Laura Garcia
Acute Care · West Nyack, NYNPI 1073675989
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $963 and has fallen 52.7% since, to $456 in 2025. Among acute care clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 47 payments — averaging $70.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$604
- AbbVie$439
- Otsuka America Pharmaceutical, Inc.$395
- EMD Serono, Inc.$328
- SK Life Science, Inc.$263
- Genentech USA, Inc.$148
- plus $1K from 12 others
What the payments were for
- Food & beverage$3,291100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 5 | $604 |
| AbbVie | 18 | $439 |
| Otsuka America Pharmaceutical, Inc. | 3 | $395 |
| EMD Serono, Inc. | 3 | $328 |
| SK Life Science, Inc. | 5 | $263 |
| Genentech USA, Inc. | 1 | $148 |
| Sage Therapeutics, LLC | 1 | $146 |
| AstraZeneca | 1 | $131 |
| Mylan Specialty L.p. | 1 | $125 |
| Calliditas Therapeutics US Inc. | 1 | $125 |
| Neurocrine Biosciences, Inc. | 1 | $125 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $121 |
| Sunovion Pharmaceuticals Inc. | 1 | $118 |
| E.r. Squibb & Sons, L.L.C. | 1 | $115 |
| Acadia Pharmaceuticals Inc | 1 | $37 |
| Astellas Pharma US Inc | 1 | $31 |
| Avanir Pharmaceuticals, Inc. | 1 | $22 |
| Pfizer | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,293 in reported general payments places this provider in the 90th percentile of 980 acute care providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 11 | $8,446 |
| Memantine Hcl | 51 | $1,473 |
| Donepezil Hcl | 115 | $810 |
| Pregabalin | 15 | $713 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 25 | $571 |
| Gabapentin | 34 | $510 |
| Quetiapine Fumarate | 15 | $324 |
| Duloxetine Hcl | 11 | $265 |
| Lamotrigine | 30 | $229 |
| Amitriptyline Hcl | 11 | $171 |
| Primidone | 17 | $66 |
Paid to pharmacies, not to this prescriber.
Other acute care in West Nyack
- Daniel VerinaNew York$464K
- Michele BiscossiSaratoga Springs$64K
- Heidi YipCanandaigua$29K
- Katie WorthingtonNew York$25K
- Loveth AdenugaNew York$20K
- Katherine DukeNew York$18K
- Ann HarrisBrooklyn$14K
- Marcel RozarioMedina$10K
- Julie Anne RoldanNew York$10K
- Dana SiscoSuffern$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.